Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Slides:

Advertisements

Similar presentations

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Advertisements

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Covering the Bases in Cardioversion

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

NOACs for Cancer-Associated Thrombosis:

Atrial Fibrillation and PCI

Updates in Anticoagulation: What Did We Learn From ESC 2017?

Long-Term Treatment of VTE: Case Studies

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

The ABCs of AF.

Access to NOAC Therapy:

NOACs in Clinical Practice: Are They All the Same?

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

Anticoagulation Highlights From the American Heart Association Meeting 2017.

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Call to Action on Cryptogenic Stroke

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

How to Adjust Anticoagulant Dosing

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Real-World Safety of NOACs: What Do We Know Today?

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

TAVR and the Risk of Thrombosis

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

Watching for the Patient With AF: Latest Advances and Technologies

Learning Objectives Classification of VTE Goals of VTE Treatment.

Risk Stratification in CAD and PAD

Oral Anticoagulation in AF

Real-World Evidence in VTE

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

NOACs in AF: Consequences of Underdosing and NonAdherence

Anticoagulation and Thrombosis Management

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

A Time for Change for Managing Patients With VTE Who Have Cancer

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Updates in Anticoagulation: Key Sessions at ESC 2017

Managing Pulmonary Embolism Posthospital Discharge

Program Goals Background: Anticoagulation in Patients With VTE.

NOACs in AF: Consequences of Underdosing and NonAdherence

Factor Xa Inhibitors in Coronary Artery Disease

The ABCs of AF.

5 Good Minutes on Atrial Fibrillation-related Stroke

How to Adjust Anticoagulant Dosing

Antiarrhythmic Drugs in AF

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Extraordinary Cases in Stroke Prevention

What's New in NOACs in AF?.

Presentation transcript:

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

NOACs in Stroke Prevention in AF

Defining Real-World Evidence

Uses of RWE

Appraising the Quality of RWE

Appraising the Quality of RWE (cont)

Appraising the Quality of RWE (cont)

XANTUS

XANTUS, XANTUS-EL, XANAP

XANTUS Rivaroxaban Treatment Profile

XANTUS Pooled Overall Safety Outcomes

XANTUS Risk Factors for Major Bleeding

XANTUS Modeled Effect of Modifiable Risk Factors

XANTUS Outcomes According to Dosing

XANTUS Inappropriate Dosing

Goals for Registry Data

Lessons From Registry Data: #1

Lessons From Registry Data: #2

Lessons From Registry Data: #3

NOACs in Frail Patients

NOACs in Frail Patients Results

Summary

Abbreviations

Abbreviations (cont)